160 related articles for article (PubMed ID: 31189966)
1. Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study.
Lee JY; Jang SY; Nam CM; Kang ES
Sci Rep; 2019 Jun; 9(1):8532. PubMed ID: 31189966
[TBL] [Abstract][Full Text] [Related]
2. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
Arvind A; Memel ZN; Philpotts LL; Zheng H; Corey KE; Simon TG
Metabolism; 2021 Jul; 120():154780. PubMed ID: 33891949
[TBL] [Abstract][Full Text] [Related]
4. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
[TBL] [Abstract][Full Text] [Related]
6. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study.
Kim G; Jang SY; Nam CM; Kang ES
J Hepatol; 2018 Mar; 68(3):476-484. PubMed ID: 29107150
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hepatocellular carcinoma risk between patients treated with glimepiride and gliclazide.
Lee JY; Kim G; Lee YH; Lee BW; Cha BS; Nam CM; Kang ES
Diabetes Metab; 2019 Jan; 45(1):83-85. PubMed ID: 28778564
[No Abstract] [Full Text] [Related]
8. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
[TBL] [Abstract][Full Text] [Related]
9. Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
Cho EH; Han K; Kim B; Lee DH
Medicine (Baltimore); 2020 Jul; 99(29):e21236. PubMed ID: 32702900
[TBL] [Abstract][Full Text] [Related]
10. Anti-diabetic medications and the risk for colorectal cancer: A population-based nested case-control study.
Shin CM; Kim N; Han K; Kim B; Jung JH; Oh TJ; Lee DH
Cancer Epidemiol; 2020 Feb; 64():101658. PubMed ID: 31887708
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
12. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection.
Kawaguchi T; Taniguchi E; Morita Y; Shirachi M; Tateishi I; Nagata E; Sata M
Liver Int; 2010 Mar; 30(3):479-86. PubMed ID: 20040053
[TBL] [Abstract][Full Text] [Related]
13. Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
Hassan MH; Abd-Allah GM
Pak J Pharm Sci; 2015 Sep; 28(5):1723-30. PubMed ID: 26408873
[TBL] [Abstract][Full Text] [Related]
14. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
Donadon V; Balbi M; Casarin P; Vario A; Alberti A
World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086
[TBL] [Abstract][Full Text] [Related]
15. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
16. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
Abdelmoneim AS; Eurich DT; Senthilselvan A; Qiu W; Simpson SH
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
[TBL] [Abstract][Full Text] [Related]
17. Risk of severe hypoglycemic events from amiodarone-sulfonylureas interactions: A population-based nested case-control study.
Lai JH; Wang MT; Wu CC; Huang YL; Lu CH; Liou JT
Pharmacoepidemiol Drug Saf; 2020 Aug; 29(8):842-853. PubMed ID: 32483856
[TBL] [Abstract][Full Text] [Related]
18. Association of fasting serum glucose level and type 2 diabetes with hepatocellular carcinoma in men with chronic hepatitis B infection: A large cohort study.
Kim K; Choi S; Park SM
Eur J Cancer; 2018 Oct; 102():103-113. PubMed ID: 30189372
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea.
Yi SW; Choi JS; Yi JJ; Lee YH; Han KJ
Cancer; 2018 Jul; 124(13):2748-2757. PubMed ID: 29669170
[TBL] [Abstract][Full Text] [Related]
20. Is gliclazide a sulfonylurea with difference? A review in 2016.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
